NCT03336333 2026-03-09SEQUOIABeOne MedicinesPhase 3 Active not recruiting590 enrolled 12 charts 1 FDA
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT02242942 2025-11-06Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaHoffmann-La RochePhase 3 Completed445 enrolled 22 charts 1 FDA